UROTHELIAL CANCER TREATMENT MARKET ANALYSIS
Global Urothelial Cancer Treatment Market – Dynamics
Rising incidences of bladder cancer is expected to propel growth of the global urothelial cancer treatment market over the forecast period. For instance, on May 2019, according to the American Society of Clinical Oncology (ASCO), May 2019, urolthelial cancer makes up about 90% of all the bladder cancers.
Moreover, increasing number of new bladder cancer cases is also anticipated to drive the growth of the market during the forecasted period. For instance, according to the World Cancer Research Fund, nearly 550,000 new cases of bladder cancer were reported worldwide in 2018.
Major players are adopting expansion strategies to further strengthen their market position through mergers, agreements and acquisitions which is expected to drive the urothellial cancer treatment market over the forecast period. For instance, in December 2019, Seattle Genetics, Inc. and Astellas Pharma Inc. entered into a collaboration with Merck & Co., Inc., to initiate a phase 3 clinical trial to evaluate enfortumab vedotin and KEYTRUDA for the treatment of metastatic urothelial cancer.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
